Publications

11 The heterogeneous genomic and immune landscapes of lethal metastatic breast cancer

Authors: L De Mattos-Arruda, SJ Sammut, EM Ross, R Bashford-Rogers, E Greenstein, OM...

Research group: Markowetz Group

E-pub date: 1 Jun 2018

Journal name: ESMO Open

PO-329 Rejecting neutral tumour evolution across human cancer types

Authors: M Tarabichi, I Martincorena, M Gerstung, F Markowetz, P Spellman, Q Morris,...

Research group: Markowetz Group

E-pub date: 1 Jun 2018

Journal name: ESMO Open

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.

Authors: O Sonzogni, J Haynes, LA Seifried, YM Kamel, K Huang, MD BeGora, FA Yeung, ...

Research group: Hannon Group

E-pub date: 1 Jun 2018

Journal name: PLoS Biol

Corrigendum to “GoldCLIP: Gel-omitted Ligation-dependent CLIP” [Genomics Proteomics Bioinformatics 16 (2) (2018) 136-143].

Authors: J Gu, M Wang, Y Yang, D Qiu, Y Zhang, J Ma, Y Zhou, GJ Hannon, Y Yu

Research group: Hannon Group

E-pub date: 1 Jun 2018

Journal name: Genomics Proteomics Bioinformatics

PO-489 TP53 mutations and focal genomic amplifications for ctDNA detection in high-grade serous ovarian carcinoma

Authors: T Goranova, G Macintyre, D De Silva, D Ennis, I McNeish, J Brenton

Research group: Brenton Group

E-pub date: 1 Jun 2018

Journal name: ESMO Open

PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer

Authors: E Moore, D Chandrananda, A Piskorz, F Mouliere, T Goranova, H Addley, R Cra...

Research group: Brenton Group,

E-pub date: 1 Jun 2018

Journal name: ESMO Open

Detection of early neoplasia in Barrett’s esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue.

Authors: AA Neves, M Di Pietro, M O'Donovan, DJ Waterhouse, SE Bohndiek, KM Brindle,...

Research group: , Bohndiek Group

E-pub date: 1 Jun 2018

Journal name: Endoscopy

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.

Authors: ME Mayerhoefer, M Raderer, U Jaeger, P Staber, B Kiesewetter, D Senn, FA Ga...

Research group:

E-pub date: 1 Jun 2018

Journal name: Eur J Nucl Med Mol Imaging

Filters

Research Groups

Core Facilities

Start date

End date

11 The heterogeneous genomic and immune landscapes of lethal metastatic breast cancer

PO-329 Rejecting neutral tumour evolution across human cancer types

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.

Corrigendum to “GoldCLIP: Gel-omitted Ligation-dependent CLIP” [Genomics Proteomics Bioinformatics 16 (2) (2018) 136-143].

PO-489 TP53 mutations and focal genomic amplifications for ctDNA detection in high-grade serous ovarian carcinoma

PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer

Detection of early neoplasia in Barrett’s esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue.

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

11 The heterogeneous genomic and immune landscapes of lethal metastatic breast cancer

PO-329 Rejecting neutral tumour evolution across human cancer types

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.

Corrigendum to “GoldCLIP: Gel-omitted Ligation-dependent CLIP” [Genomics Proteomics Bioinformatics 16 (2) (2018) 136-143].

PO-489 TP53 mutations and focal genomic amplifications for ctDNA detection in high-grade serous ovarian carcinoma

PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer

Detection of early neoplasia in Barrett’s esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue.

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.